Background
Researchers have indicated that they want access to novel target antibodies quickly to aid in their research. IMGENEX is pleased to be able to offer researchers access to cutting-edge products that are still in the process of characterization/validation. IMGENEX’s ‘IMX’ antibody line is shown by ELISA to bind to the peptide used as immunogen. Investigators should empirically determine the suitability of the antibody, including optimal dilutions, for other applications of interest.
 |
We cannot guarantee that the yet-to-be-fully validated antibody will work in any application other than in an ELISA against the peptide used as immunogen and therefore cannot offer a refund if the antibody does not work in your application. |
|
The antibody is offered at a lower price compared to a more highly validated antibody. |
|
We are not able to provide the immunogen for the antibodies, but do provide the amino acid sequence. |
These antibodies are not fully validated and we appreciate your feedback. Customer feedback is used to help generate testing methodologies which can lead to further product validation or withdrawal.
The caudal type homeo box transcription factor 1 (CDX1) and CDX2 are candidates for directing intestinal development, differentiation, and maintenance of the intestinal phenotype. CDX1 is a 265-amino-acid protein with 85% identity to mouse Cdx1 (98% identity, including conservative amino acid changes). CDX1 and CDX2 expression is widely present in the human intestinal and colonic mucosae, but not in the gastric mucosa, suggesting a possible role in the terminal differentiation of the intestine. Decrease in human CDX1 and/or CDX2 expression is associated with colorectal tumorigenesis. On the other hand, increased CDX1 expression is associated with chronic atrophic gastritis. |
